Package 0003-2328-22

{"route": ["INTRAVENOUS"], "spl_id": "ecc3bf01-2632-4c2e-85aa-e34da43d25f2", "openfda": {"nui": ["N0000182635", "N0000182634", "N0000182157"], "unii": ["6T8C155666"], "rxcui": ["1657005", "1657007", "1657012", "1657013"], "spl_set_id": ["2265ef30-253e-11df-8a39-0800200c9a66"], "pharm_class_pe": ["Increased T Lymphocyte Activation [PE]"], "pharm_class_epc": ["CTLA-4-directed Blocking Antibody [EPC]"], "pharm_class_moa": ["CTLA-4-directed Antibody Interactions [MoA]"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-USE in 1 CARTON (0003-2328-22)  / 40 mL in 1 VIAL, SINGLE-USE", "package_ndc": "0003-2328-22", "marketing_start_date": "20110325"}], "brand_name": "YERVOY", "product_id": "0003-2328_ecc3bf01-2632-4c2e-85aa-e34da43d25f2", "dosage_form": "INJECTION", "pharm_class": ["CTLA-4-directed Antibody Interactions [MoA]", "CTLA-4-directed Blocking Antibody [EPC]", "Increased T Lymphocyte Activation [PE]"], "product_ndc": "0003-2328", "generic_name": "ipilimumab", "labeler_name": "E.R. Squibb & Sons, L.L.C.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "YERVOY", "active_ingredients": [{"name": "IPILIMUMAB", "strength": "5 mg/mL"}], "application_number": "BLA125377", "marketing_category": "BLA", "marketing_start_date": "20110325", "listing_expiration_date": "20261231"}